A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes.

After 12 weeks of treatment, participants in the R-Vera treatment groups showed a trend of increase in HOMA2-β from baseline compared with participants in the placebo group, despite the fact that participants in the R-Vera treatment groups already had higher HOMA2-β score relative to participants in the placebo group at baseline ( Table 2 ).

also in 53,322 other papers